The estimated Net Worth of Robert W. Ross is at least $1.33 Millón dollars as of 1 August 2023. Robert Ross owns over 16,713 units of Surface Oncology Inc stock worth over $89,017 and over the last 6 years he sold SURF stock worth over $428,592. In addition, he makes $809,790 as Chief Medical Officer at Surface Oncology Inc.
Robert has made over 10 trades of the Surface Oncology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 16,713 units of SURF stock worth $15,710 on 1 August 2023.
The largest trade he's ever made was selling 33,500 units of Surface Oncology Inc stock on 21 July 2021 worth over $204,350. On average, Robert trades about 6,425 units every 104 days since 2019. As of 1 August 2023 he still owns at least 83,193 units of Surface Oncology Inc stock.
You can see the complete history of Robert Ross stock trades at the bottom of the page.
Dr. Robert W. Ross M.D. serves as Chief Medical Officer of the Company. Prior to joining us, Dr. Ross served as Head of Oncology at bluebird bio, Inc. from October 2015 to October 2016, Senior Vice President of Clinical Development and Pharmacovigilance, from January 2015 to October 2016, and Vice President of Clinical Development, from October 2012 to January 2015. Prior to that, he worked at Infinity Pharmaceuticals, Inc. from October 2007 to October 2012. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Center from July 2003 to August 2007, and then maintained a clinical practice at Dana Farber Cancer from August 2007 to October 2015. Dr. Ross received a B.S. in Biological Sciences and a B.A. in Philosophy from Stanford University, an M.S. in Medical Science as part of the Clinical Investigator Training Program from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco.
As the Chief Medical Officer of Surface Oncology Inc, the total compensation of Robert Ross at Surface Oncology Inc is $809,790. There are 2 executives at Surface Oncology Inc getting paid more, with J. Jeffrey Goater having the highest compensation of $1,642,260.
Robert Ross is 46, he's been the Chief Medical Officer of Surface Oncology Inc since 2016. There are 11 older and 4 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Surface Oncology Inc executives and other stock owners filed with the SEC include: